Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.60
Bid: 2.50
Ask: 2.70
Change: -0.05 (-1.89%)
Spread: 0.20 (8.00%)
Open: 2.65
High: 2.65
Low: 2.60
Prev. Close: 2.65
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ValiRx Raises GBP2.5 Million In Subscription, Agrees Equity Swap (ALLISS)

Wed, 16th Sep 2015 07:27

LONDON (Alliance News) - Life sciences company ValiRx PLC on Wednesday said it has raised GBP2.5 million through a subscription agreement with YA Global Master SPV Ltd.

YA Global Master has agreed to subscribe for 8.2 million ValiRx shares at 30.018 pence per share. ValiRx shares were down 9.3% to 27.66 pence on Wednesday morning, one of the worst performers in the AIM All-Share.

The company said the funds raised in the subscription will be used to advanced its therapeutic developments, biomarker programmes and for general working capital purposes.

In addition, ValiRx and Yorkville, which runs the YA Global Master vehicle, have agreed an equity swap concerning 6.4 million of the subscription shares.

Under that agreement, ValiRx will pay Yorkville GBP1.0 million, and Yorkville in turn will pay ValiRx monthly payments of GBP83,333.33 adjusted by reference to a formula related to the difference between the prevailing market price of the company's shares in any month and a benchmark price of 34.21 pence.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
5 Feb 2015 08:18

ValiRx Buys Finnish Gene Expression And Biomarker Technology

Read more
15 Jan 2015 10:36

ValiRx Expects First VAL201 Results In 1st Quarter; VAL401 Progresses

Read more
13 Nov 2014 09:47

ValiRx Enters Collaboration Agreement For GeneICE Development

Read more
3 Nov 2014 11:09

ValiRx VAL201 PhaseI/II Trial Progressing In Line With Plan

Read more
14 Oct 2014 09:22

ValiRx VAL201 Phase I/II Trial Ready To Begin Recruitment

Read more
8 Oct 2014 15:31

ValiRx Completes YA Global Master Equity Swap Deal Early

Read more
2 Sep 2014 09:27

Valirx's lung cancer treatment receives positive results

Valirx, the developer and producer of technology used in oncology therapeutics, has received positive results from the studies on one of its lung cancer treatments. The studies on treatment VAL401 were carried out by Valiseek, Valirx's joint venture company with Tangent Reprofiling, and demonstrate

Read more
2 Sep 2014 07:26

UK MORNING BRIEFING: Weir Group Leads Firm London Market On Upgrade

Read more
2 Sep 2014 06:40

ValiRx Says Preclinical Trials For VAL401 In Lung Cancer Positive

Read more
19 Aug 2014 10:08

ValiRx Narrows Half-Year Loss On Lower Costs, Progresses Pipeline

Read more
4 Aug 2014 11:12

UK MIDDAY BRIEFING: HSBC Results Below Expectations

Read more
4 Aug 2014 10:49

UK WINNERS & LOSERS: HSBC And Intertek Rise Despite Lower Profit

Read more
4 Aug 2014 07:36

ValiRx Gets Authorisation For VAL201 Trials, Shares Jump

Read more
4 Aug 2014 07:34

UK MORNING BRIEFING: UK Shares Flat Ahead Of HSBC Results

Read more
24 Jun 2014 09:23

DIRECTOR DEALINGS: ValiRx Directors Buy 5.3 Million Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.